SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the second quarter of FY 2020. During the quarter, the Company completed a consolidation of its share capital, appointed a new CEO, Dr Michael Baker, who commenced 2 January 2020 and received a refund under the R&D Tax Incentive program of $928,000.
For more information, download the attached PDF.
Download this document
